bl-m11d1
mAbexperimentalADC
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Aug 2, 2023 (NCT05924750)
Timeline
Indications
Mechanism of action
- Myeloid cell surface antigen CD33BINDING AGENT
CD33 binding agent
Chemistry & pharmacology
- Payload
- unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07255872 | Phase 2/Phase 3 (Phase 3) | Dec 31, 2025 | Baili Pharmaceutical Group |
| NCT06714591 | Phase 1 | Dec 31, 2024 | SystImmune Inc. |
| NCT05924750 | Phase 1 | Aug 2, 2023 | Baili Pharmaceutical Group, Chinese Academy of Medical Sciences |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baili Pharmaceutical Group | For profit | 2 | 2 | 2 | 2023 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2023 |
| SystImmune Inc. | For profit | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1